Retraction: miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6 (Oncology Reports (2015) 34 (2202-2210) DOI: 10.3892/or.2015.4165);MIR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6

Oncology Reports

Volumn 34, Issue 4, 2015, Pages 2202-2210

  Wen, Qiang ^a   Zhao, Jie ^a   Bai, Lin ^a   Wang, Tongtong ^a   Zhang, Haishan ^a   Ma, Qingjie ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

LRP6; MIR 126; Papillary thyroid carcinoma; Wnt catenin

Indexed keywords

BETA CATENIN; CYCLIN D1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MATRILYSIN; MESSENGER RNA; MICRORNA 126; MYC PROTEIN; WNT PROTEIN; 3' UNTRANSLATED REGION; LRP6 PROTEIN, HUMAN; MICRORNA; MIRN126 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; NONHUMAN; PAPILLARY THYROID CARCINOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; TUMOR VOLUME; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA; CELL MOTION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; THYROID TUMOR; TUMOR CELL LINE; TUMOR INVASION;

3' UNTRANSLATED REGIONS; ANIMALS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; MALE; MICE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; THYROID NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84939143586     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/OR.2021.8097     Document Type: Erratum

References (42)

1. Brown RL, de Souza JA and Cohen EE: Thyroid cancer: Burden of illness and management of disease. J Cancer 2: 193-199, 2011.
2. Nikiforova MN and Nikiforov YE: Molecular genetics of thyroid cancer: Implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8: 83-95, 2008.
3. Lang BH, Wong KP, Wan KY and Lo CY: Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection. Ann Surg Oncol 19: 1257-1263, 2012.
4. Fabian MR, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351-379, 2010.
5. Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840, 2010.
6. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
7. McManus MT: MicroRNAs and cancer. Semin Cancer Biol 13: 253-258, 2003.
8. Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol 223: 102-115, 2011.
9. Ebrahimi F, Gopalan V, Smith RA and Lam AK: MIR-126 in human cancers: Clinical roles and current perspectives. Exp Mol Pathol 96: 98-107, 2014.
10. Zhao C, Li Y, Zhang M, Yang Y and Chang L: MIR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2. Hum Cell 28: 91-99, 2015.
11. Jiang L, Tao C, He A and He X: Overexpression of MIR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate. World J Surg Oncol 12: 383, 2014.
12. Kim MK, Jung SB, Kim JS, Roh MS, Lee JH, Lee EH and Lee HW: Expression of microRNA MIR-126 and MIR-200c is associated with prognosis in patients with non-small cell lung cancer. Virchows Arch 465: 463-471, 2014.
13. Chen H, Li L, Wang S, Lei Y, Ge Q, Lv N, Zhou X and Chen C: Reduced MIR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. Oncotarget 5: 11873-11885, 2014.
14. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C and Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 3: e2557, 2008.
15. Yamaguchi T, Iijima T, Wakaume R, Takahashi K, Matsumoto H, Nakano D, Nakayama Y, Mori T, Horiguchi S and Miyaki M: Underexpression of MIR-126 and MIR-20b in hereditary and nonhereditary colorectal tumors. Oncology 87: 58-66, 2014.
16. Li Z, Li N, Wu M, Li X, Luo Z and Wang X: Expression of MIR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. Mol Cell Biochem 381: 233-242, 2013.
17. Kitano M, Rahbari R, Patterson EE, Xiong Y, Prasad NB, Wang Y, Zeiger MA and Kebebew E: Expression profiling of difficult-todiagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann Surg Oncol 18: 3443-3452, 2011.
18. Hagan JP and Croce CM: MicroRNAs in carcinogenesis. Cytogenet Genome Res 118: 252-259, 2007.
19. Osada H and Takahashi T: MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 28: 2-12, 2007.
20. Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol 774: 1-20, 2013.
21. Leonardi GC, Candido S, Carbone M, Colaianni V, Garozzo SF, Cinà D and Libra M: microRNAs and thyroid cancer: Biological and clinical significance (Review). Int J Mol Med 30: 991-999, 2012.
22. Wei WJ, Shen CT, Song HJ, Qiu ZL and Luo QY: MicroRNAs as a potential tool in the differential diagnosis of thyroid cancer: A systematic review and meta-analysis. Clin Endocrinol: Dec 16, 2014 (Epub ahead of print). doi: 10.1111/cen.12696.
23. Huang C, Cai Z, Huang M, Mao C, Zhang Q, Lin Y, Zhang X, Tang B, Chen Y, Wang X, et al: MIR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor. J Clin Endocrinol Metab 100: E204-E213, 2015.
24. Zhu H, Fang J, Zhang J, Zhao Z, Liu L, Wang J, Xi Q and Gu M: MIR-182 targets CHL1 and controls tumor growth and invasion in papillary thyroid carcinoma. Biochem Biophys Res Commun 450: 857-862, 2014.
25. Li D, Jian W, Wei C, Song H, Gu Y, Luo Y and Fang L: Downregulation of MIR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer. Int J Clin Exp Pathol 7: 7672-7680, 2014.
26. Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, Kang HY and Liu RT: Prognostic implications of MIR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab 98: E196-E205, 2013.
27. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D: MIR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15: 272-284, 2008.
28. Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, Chen CZ and Kuo CJ: Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA MIR-126. Development 135: 3989-3993, 2008.
29. Liu LY, Wang W, Zhao LY, Guo B, Yang J, Zhao XG, Hou N, Ni L, Wang AY, Song TS, et al: mir-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2. Int J Oncol 45: 1257-1265, 2014.
30. Feng X, Wang H, Ye S, Guan J, Tan W, Cheng S, Wei G, Wu W, Wu F and Zhou Y: Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IB. PLoS One 7: e52782, 2012.
31. Li H, Meng F, Ma J, Yu Y, Hua X, Qin J and Li Y: Insulin receptor substrate-1 and Golgi phosphoprotein 3 are downstream targets of MIR-126 in esophageal squamous cell carcinoma. Oncol Rep 32: 1225-1233, 2014.
32. Jia AY, Castillo-Martin M, Bonal DM, Sánchez-Carbayo M, Silva JM and Cordon-Cardo C: MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. Br J Cancer 110: 2945-2954, 2014.
33. Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie H, Zhou L, Wu J and Zheng S: MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2. J Transl Med 12: 259, 2014.
34. Joiner DM, Ke J, Zhong Z, Xu HE and Williams BO: LRP5 and LRP6 in development and disease. Trends Endocrinol Metab 24: 31-39, 2013.
35. Peröbner I, Karow M, Jochum M and Neth P: LRP6 mediates Wnt/-catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells. Int J Biochem Cell Biol 44: 1970-1982, 2012.
36. Brown SD, Twells RC, Hey PJ, Cox RD, Levy ER, Soderman AR, Metzker ML, Caskey CT, Todd JA and Hess JF: Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family. Biochem Biophys Res Commun 248: 879-888, 1998.
37. Li Y, Lu W, He X, Schwartz AL and Bu G: LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution. Oncogene 23: 9129-9135, 2004.
38. Zhang Y, Zheng D, Xiong Y, Xue C, Chen G, Yan B and Ye Q: MIR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 post-transcriptionally. FEBS Lett 588: 1913-1920, 2014.
39. Wang J, Wang X, Li Z, Liu H and Teng Y: MicroRNA-183 suppresses retinoblastoma cell growth, invasion and migration by targeting LRP6. FEBS J 281: 1355-1365, 2014.
40. Zeng XC, Liu FQ, Yan R, Yi HM, Zhang T, Wang GY, Li Y and Jiang N: Downregulation of MIR-610 promotes proliferation and tumorigenicity and activates Wnt/-catenin signaling in human hepatocellular carcinoma. Mol Cancer 13: 261, 2014.
41. Wang J, Guan X, Guo F, Zhou J, Chang A, Sun B, Cai Y, Ma Z, Dai C, Li X, et al: MIR-30e reciprocally regulates the differentiation of adipocytes and osteoblasts by directly targeting low-density lipoprotein receptor-related protein 6. Cell Death Dis 4: e845, 2013.
42. Zhang W, Shen C, Li C, Yang G, Liu H, Chen X, Zhu D, Zou H, Zhen Y, Zhang D, et al: MIR-577 inhibits glioblastoma tumor growth via the Wnt signaling pathway. Mol Carcinog: Mar 12, 2015 (Epub ahead of print).